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Purpose: To evaluate therapeutic drug monitoring (TDM) of lamotrigine (LTG) with
establishment of individual therapeutic thresholds (TT) in outpatients of a tertiary
epilepsy centre on monotherapy.
Methods: In the outpatient clinic of the Danish Epilepsy Centre, Dianalund, all
patients treated in 2004 with LTG monotherapy were identified. Patients who had
not reported seizures or adverse reactions in the last 6 months were considered
seizure free and well-medicated on LTG monotherapy, and were further evaluated.
Plasma levels from routine LTG TDM obtained by reversed-phase high-pressure liquid
chromatography (HPLC) during up-titration were used to calculate the TT for each
patient as the mean of the highest subtherapeutic and the lowest therapeutic level.
Results: Eighty-two patients undergoing LTG monotherapy were reported seizure
free as defined above. In 34 the TT could not be calculated because they became
seizure free on the first chosen dose. TTs of the remaining 48 patients ranged from 4.0
to 42.0 mmol/l. There were no differences between children and adults, and between
generalized and localization-related epilepsies. The therapeutic levels of patients
with undefined TT tended to be lower. The level—dose ratio in both groups varied only
moderately indicating absence of major exogenous influences.
Conclusion: Even in patients of a tertiary referral centre only a minority had high TTs
and needed therapeutic levels in a range where toxicity is increasingly observed. TDM
appears useful in LTG treatment both for the establishment of individual reference
ranges and for the identification of the individual level-to-dose ratio.
# 2007 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.Introduction
The literature about the use of therapeutic drug
monitoring (TDM) in lamotrigine (LTG) treatment is* Corresponding author. Tel.: +45 58 27 11 73;
fax: +45 58 27 11 66.
E-mail address: kirsns@vestamt.dk (K.A. Nielsen).
1059-1311/$ — see front matter # 2007 British Epilepsy Association
doi:10.1016/j.seizure.2007.11.023controversial. Kilpatrick et al.1 and Bartoli et al.2
indicated no clear-cut relationship between clinical
response, toxicity and serum concentrations, and
Chong and Dupuis3 in a review concluded that ‘‘clear
relationships between concentration and pharma-
cologic response (either efficacy or toxicity) have
not been demonstrated’’. However, Perucca4 and. Published by Elsevier Ltd. All rights reserved.
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LTG is useful because of its pharmacokinetic proper-
ties. Several studies suggested appropriate ranges
of optimal serum concentrations and therapeutic
intervals, based on determination of median con-
centrations among responders on moderate dose
versus median concentrations among non-respon-
ders exhibiting side effects,6,7 but a considerable
overlap between responders and non-responders
was found, as reviewed by Johannessen et al.8
and Johannessen.9
The classic investigations that have established
TDM as a tool for better treatment have used a
different approach. They compared plasma levels
in a period when the patient still had seizures with
levels when seizure control was obtained. Likewise,
in patients on high doses, plasma levels in the
presence of signs and symptoms of overdose were
compared with subtoxic levels. With these determi-
nations, individual thresholds for sufficient thera-
peutic action and dose-dependent side effects can
be identified. This was particularly important for
Phenytoin whose non-linear kinetics and narrow
therapeutic index limit the significance of doses,
and therapeutic drug monitoring (TDM) introduces a
much more reliable parameter.10 Similar investiga-
tions have rarely been performed for the newer
AEDs including LTG which have easier kinetics and
a wider therapeutic range. Hirsch et al.,11 however,
have shown that the incidence of toxicity increased
in clear relation to increasing LTG serum concentra-
tions. At levels of 10—15 mg/ml (39—59 mmol/l)
24%, and above 20 mg/l (78 mmol/l) 59% of patients
showed signs of toxicity whereas others required
and tolerated levels above 20 mg/l to obtain full
seizure control.
Sabers et al.12,13 using plasma level monitoring
have shown that co-medication of LTG with oral
contraceptives impairs seizure control by induc-
tion of LTG metabolism. Without TDM this clinical
important interaction could not have been
detected, and it was followed up by the investiga-
tion of LTG during pregnancy14 which is now con-
sidered an indication for TDM of LTG.15 A long-term
survey of LTG monitoring in an Australian Labora-
tory revealed a 2.9-fold increase of LTG assay
requests over a 7-year period from 1996 to 2003,
indicating a wide clinical use of LTG assays in
clinical practice of today.16
In the Danish Epilepsy Centre, Dianalund, TDM is
performed routinely with every dosage step in
patients undergoing LTG therapy. In this paper we
report findings with individual LTG therapeutic
thresholds (TTs) as defined by longitudinal TDM in
patients who were titrated to full seizure control
with LTG in monotherapy.Individual TTs are calculated values that are
useful in the LTG treatment of patients undergoing
stepwise titration. Individual TTs are not directly
related to the general therapeutic index of any
drug. They rather define the minimum level which
creates seizure freedom in the individual patient.
The TT is more accurate than the ‘‘therapeutic
level’’ where seizure control was achieved because,
if the therapeutic dose was not titrated, the ther-
apeutic level may be considerably higher than
needed for seizure control.
The TT alone also does not inform on the entire
individual therapeutic range whose upper limit is
defined by a toxic threshold. In successfully treated
patients like those reported here this is only rarely
reached.Materials and methods
Patients
The files of all patients who in 2004 were seen in the
outpatient clinic at the Danish Epilepsy Centre,
Dianalund were screened to identify those who were
treated with LTG monotherapy. Among these, the
patients who had not reported seizures or adverse
reactions related to the antiepileptic medication in
the previous 6 months were identified. This group of
patients was considered seizure free with well-tol-
erated LTG monotherapy. To define the individual
therapeutic threshold (TT) for each of these
patients, plasma levels found at routine LTG TDM
during stepwise titration to seizure control were
used. Only data from patients who had not fully
responded to an initial LTG dose, but needed titra-
tion to a higher dose to become seizure free were
used for the calculation of TTs. Plasma levels were
included only if they were determined at a moment
when the patient was on LTG monotherapy and
could be considered free from possible pharmaco-
kinetic interactions of present or previous co-med-
ications. The only exception was one patient where
the increase from the subtherapeutic to the indivi-
dually therapeutic LTG level was due not to an
increase of dose which remained the same, but to
termination of hormonal contraception.
Therapeutic drug monitoring (TDM)
Plasma levels were morning trough levels. The LTG
concentration was estimated by use of reversed-
phase high-pressure liquid chromatography (HPLC)
according to Croci et al.17 in combination with UV
detection at 306 nm of the elution solution followed
by calculation of the area of the elution peak. Based
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Figure 1 Distribution of therapeutic thresholds (TTs) in
48 patients who became seizure free during stepwise up-
titration of LTG monotherapy in response to seizures, TTs
were defined as mean of the highest subtherapeutic andon correlation to standard curves the concentration
of LTG was given in mmol/l with a cut-off value
<1 mmol/l and linear correlation up to 125 mmol/l.
Therapeutic threshold (TT)
The TT cannot be determined directly, and there is
no generally accepted method of defining it. In this
investigation, TTwas calculated as the mean of the
highest plasma level where seizures still occurred,
and the lowest level where they were controlled.
Individually, the true TT may be closer to either the
subtherapeutic level or the therapeutic level, but in
a drug with linear kinetics no systematic bias is to be
expected, and in the absence of precise measure-
ments, this seems to be an adequate operational
measure.18the lowest therapeutic plasma level.Results
A total of 82 patients were seizure free with well-
tolerated LTG monotherapy as defined above. Of
these, 34 had become seizure free on the initial LTG
dose. Their TTs could not be calculated because no
highest subtherapeutic plasma levels exist. The
individual TTs could be determined in the remaining
48 patients.
The characteristics of the 48 patients are given in
Table 1. The ages ranged from 4 to 73 years, and 40
patients were diagnosed with localization-related
epilepsy whereas 8 had generalized epilepsy. Among
the localization-related epilepsies in adults, tem-
poral lobe epilepsies covered over 50% (18 out of 32
cases) as expected from earlier reports on difficult-
to-treat patients referred to tertiary centres.19 The
generalized epilepsies comprised cases of Juvenile
myoclonic epilepsy (4) and idiopathic generalized







Temporal lobe 18 1
Occipital lobe 2 1
Idiopathic rolandic 0 4
Multifocal 0 2
Unidentified 12 0
Generalized epilepsies 8 0
Juvenile myoclonic 4
Other idiopathic 4The calculated TTs of the 48 patients in mono-
therapy are presented in Fig. 1. They ranged from4.0
to 42.0 mmol/l. Patients with localization-related
epilepsies had TTs between 5.5 and 42.0 mmol/l,
and patients with generalized epilepsies ranged from
4.0 to 31.0 mmol/l. In children, the TTs ranged from 7
to 26 mmol/l, and in adults from 4 to 42 mmol/l.
Between thegroups (localization-relatedvs. general-
ized epilepsies) there was no difference.
To compare plasma levels resulting in full seizure
control in patients with and without defined TTs, we
looked at the lowest therapeutic plasma levels in
both groups (Fig. 2).
Themean therapeutic plasma level of the patients
with defined TT was 23.2 mmol/l with S.D.
10.60 mmol/l. In the patients who became seizure
free with the first chosen dose, the respective values
were 13.3  7.27 mmol/l (Fig. 3). Thus, the apparentFigure 2 Level—dose ratio of the therapeutic levels (not
thresholds) of 48 patients with known TTs and 34 patients
who became seizure free with the first chosen dose of LTG
in monotherapy.
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Figure 3 Comparison of therapeutic levels of the groups
with and without identified TT. The patients responding to
the first dose seem as a group to require lower plasma
levels to be seizure free, but the difference is not sig-
nificant due to large interindividual variability with some
overlap of standard deviations.clear difference between the two groups is not sta-
tistically significant due to the considerable inter-
individual variability with a slight overlap of standard
deviations. Among the patients with a calculated TT,
a dose of 1200 mg in one patient resulted in a plasma
level of 47 mmol/l,whichwas thehighest therapeutic
and non-toxic level of LTG in the present study. The
highest therapeutic level in a patient without known
TTwas32atadoseof200 mg.Thetherapeuticplasma
levels of 8 of the 82 patientswere 35 mmol/l ormore,
all with localization-related epilepsy (no significant
difference from generalized epilepsy, Fisher’s exact
test).
The level—dose ratios (LDRs, Fig. 2) showed con-
siderable interindividual variability but no systema-
tic deviations from the mean, and did not differ
between the two groups with and without defined
TTs.Discussion
The literature proposing that TDM for LTG is irre-
levant because neither therapeutic nor toxic
effects can be correlated with plasma levels,3 is
based on comparisons of plasma LTG levels in
patient groups that were seizure free versus still
having seizures. The plasma levels showed no group
differences.
This, however, is not an adequate method to
establish the use of therapeutic monitoring of an
AED because it compares heterogeneous groups, i.e.
drug-resistant patients with others who are well
treatable. TDM is based upon the comparison ofdrug level determinations with subtherapeutic
and therapeutic as well as subtoxic and toxic doses
in individual patients.10
Our findings demonstrate that individual thera-
peutic thresholds can be defined in LTG and support
the view of Fro¨scher et al.,7 Hirsch et al.,11 Johan-
nessen,9 Johannessen et al.,8 Johannessen and Tom-
son5 and Perucca4 that TDM has a place in the
management of epilepsy with this drug. This is
further supported by the interindividual variability
of LDRs which makes it impossible to relate the
therapeutic effects directly to the doses. In spite
of their individual variability, the LDRs for the whole
cohort did not display any systematic deviations
which would indicate major influences of confound-
ing factors like frequent compliance problems or
interactions with other medication like contracep-
tives12,13 although both certainly occurred in indi-
vidual cases. Nor did the distribution of LDRs differ
in the two groups (Fig. 2). Obviously, the differences
of the LDRs together with the titration scheme
result in individual differences of the interval
between the highest subtherapeutic and lowest
therapeutic levels from which the TT is calculated,
and its definition is the more accurate the narrower
the interval. But even the less accurate TTs clearly
provide a clinically more reliable orientation than
an individual therapeutic level which was reached
without titration.
The wide ranges of TTs and therapeutic levels
reflect the variability of the patients’ responses to
treatment. It is remarkable that even in this sample
of patients who are treated in a tertiary referral
centre for epilepsy, the TTs for LTG of most patients
are in a low to moderate range. Only a small min-
ority have therapeutic levels above 40 mg/ml, i.e.
in a range where toxicity is found in as much as one-
fourth of patients.11 These are the patients with an
individually narrow reference range for a drug
which in general is known for a broad therapeutic
index.
Although there is a slight overlap of standard
deviations between the groups with and without
defined TTs, due to the high interindividual variation
of therapeutic levels, these clearly tend to be lower
in the group of patients who responded to the first
chosen dose, which is consistent with the findings of
Wolf et al.18 and confirms that they represent a
relatively benign segment of patients.
In the present study we looked at individual
therapeutic thresholds as a tool to identify an indi-
vidual medication scheme for each patient irrespec-
tively of general therapeutic indexes. A ‘‘start low—
go slow’’ titration allows the clinician to adjust long-
term treatment to a dose which is just above the TT
and minimizes the risk of toxicity.
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Even in patients of a tertiary referral centre only a
minority had high TTs and needed therapeutic levels
in a range where toxicity is increasingly observed.
TDM appears useful in LTG treatment both for the
establishment of individual reference ranges and for
the identification of the individual level-to-dose
ratio. Seizure free patients were subsequently kept
on LTG doses that gave TDM serum concentrations as
low as possible above the calculated TT concentra-
tion in order to continue full seizure control and
avoid developments of unacceptable adverse reac-
tions.Acknowledgements
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